newsfilter
← Latest News
Business Wire·

Acceleron Presents Interim Results from the Open-label Extension of the PULSAR Phase 2 Trial of Sotatercept in Patients with Pulmonary Arterial Hypertension (PAH) at the American Thoracic Society 2021 International Conference

- Data presented show maintained or improved responses in multiple efficacy endpoints among patients treated with sotatercept plus stable background therapy for up to 48 weeks - - Patients receiving placebo plus stable background therapy during the 2